Home/Filings/4/0001104659-23-082735
4//SEC Filing

Wu Jinzi Jason 4

Accession 0001104659-23-082735

CIK 0001400118other

Filed

Jul 19, 8:00 PM ET

Accepted

Jul 20, 4:19 PM ET

Size

15.1 KB

Accession

0001104659-23-082735

Insider Transaction Report

Form 4
Period: 2023-07-18
Transactions
  • Disposition to Issuer

    Stock Option (Right to Buy)

    2023-07-1823,2160 total
    Exercise: $6.36Exp: 2029-04-27Common Stock (23,216 underlying)
  • Award

    Stock Option (Right to Buy)

    2023-07-18+23,21623,216 total
    Exercise: $6.36Exp: 2029-04-27Series A Common Stock (23,216 underlying)
  • Conversion

    Series A Common Stock

    2023-07-18+1,654,7011,654,701 total(indirect: By AP11 Limited)
  • Conversion

    Series E Preferred Stock

    2023-07-18108,471,6340 total(indirect: By AP11 Limited)
    Series A Common Stock (1,364,793 underlying)
  • Conversion

    Series F Preferred Stock

    2023-07-1823,041,4740 total(indirect: By AP11 Limited)
    Series A Common Stock (289,908 underlying)
Footnotes (4)
  • [F1]Upon closing of the Issuer's initial public offering, each share of Series E Preferred Stock and Series F Preferred Stock (collectively, the "Preferred Stock") automatically converted on a 79.4784-to-one basis into shares of the Issuer's Series A Common Stock. The Preferred Stock had no expiration date.
  • [F2]Shares held directly by AP11 Limited, a subsidiary of Ascletis Pharma Inc. ("Ascletis"). The Reporting Person is founder, chairman and chief executive officer of Ascletis. The Reporting Person disclaims Section 16 beneficial ownership of the shares reported herein except to the extent of his pecuniary interest therein, if any, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of any of the reported shares for purposes of Section 16 or any other purpose.
  • [F3]Pursuant to a reclassification exempt under Rule 16b-7 and Rule 16b-3, each share of Common Stock was reclassified into one share of Series A Common Stock.
  • [F4]The shares underlying this option are fully vested and exercisable as of the date hereof.

Issuer

Sagimet Biosciences Inc.

CIK 0001400118

Entity typeother

Related Parties

1
  • filerCIK 0001858174

Filing Metadata

Form type
4
Filed
Jul 19, 8:00 PM ET
Accepted
Jul 20, 4:19 PM ET
Size
15.1 KB